Cargando…
Targeting IAP proteins in combination with radiotherapy
The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436972/ https://www.ncbi.nlm.nih.gov/pubmed/25927408 http://dx.doi.org/10.1186/s13014-015-0399-3 |
_version_ | 1782372163135733760 |
---|---|
author | Fulda, Simone |
author_facet | Fulda, Simone |
author_sort | Fulda, Simone |
collection | PubMed |
description | The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy. Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy. |
format | Online Article Text |
id | pubmed-4436972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44369722015-05-20 Targeting IAP proteins in combination with radiotherapy Fulda, Simone Radiat Oncol Review The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy. Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy. BioMed Central 2015-04-26 /pmc/articles/PMC4436972/ /pubmed/25927408 http://dx.doi.org/10.1186/s13014-015-0399-3 Text en © Fulda; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Fulda, Simone Targeting IAP proteins in combination with radiotherapy |
title | Targeting IAP proteins in combination with radiotherapy |
title_full | Targeting IAP proteins in combination with radiotherapy |
title_fullStr | Targeting IAP proteins in combination with radiotherapy |
title_full_unstemmed | Targeting IAP proteins in combination with radiotherapy |
title_short | Targeting IAP proteins in combination with radiotherapy |
title_sort | targeting iap proteins in combination with radiotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436972/ https://www.ncbi.nlm.nih.gov/pubmed/25927408 http://dx.doi.org/10.1186/s13014-015-0399-3 |
work_keys_str_mv | AT fuldasimone targetingiapproteinsincombinationwithradiotherapy |